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Abstract
Purpose: Trabecular surgery has been introduced to overcome the complications of traditional glaucoma surgery
(trabeculectomy, shunt surgery). To evaluate clinically the number and type of complications of a new trabecular
bypass in a one site clinical group of phakic patients.
Methods: Intraoperative complications of phakic patients undergoing consecutive trabecular stent implantation
(Hydrus-Ivantis) by a single surgeon were evaluated. The patients were evaluated at 1 month, 3 months and at 1
year considering visual acuity, visual field, and gonioscopy.
Results: 41 caucasic patients (12 males and 29 females) with a mean age of 67.4 ± 8.5 years (range: 49-84) were
included in the study. All patients had a diagnosis of primary open angle glaucoma with a mean visual field MD of
-4.4 and a PSD of 4.3. The mean cup to disk ratio was 0.7 ± 0.2. Pre-operative BCVA was 20/23, the mean
medicated IOP was 19.8± 3.4 and the mean number of medications was 1.6. At the end of surgery two patients
presented a hyphema (>2mm). In one patient, the stent was repositioned during the surgical procedure. 36
patients were followed up to 3 months and 33 up to one year. The IOP decreased to 17,5 ± 3.3 at three months
and to 18 ± 3.2 at one year. At 3 months 19,4% and at one year 42,4% of the patients were medicated (mean
number of medications: 0.4 and 0.9 respectively). During the follow up no patient had a BCVA loss ≥ 2 Snellen
lines. Cup disk ratio and visual field MD were not statistically significant compared to baseline. In 6 patients new
peripheral anterior synechiae (PAS) were observed. The occurrence of PAS did not modify the IOP nor required
additional medical or surgical therapy.
Conclusions: The Hydrus trabecular stent allowed a significant reduction of therapy in this group of phakic
patients, with 57,6% unmedicated patients up to one year. The mean number of medications decreased
significantly compared to baseline (1.6 vs 0.9; p<0.05). Mild intraocular complications were observed. During the
follow-up, some patients developed peripheral anterior synechiae which did not seem to be clinically significant.
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